Parathyroid carcinoma

Current Opinion in Oncology

Volumn 18, Issue 1, 2006, Pages 16-22

  Rodgers, Steven E ^a   Perrier, Nancy D ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Carcinoma; Hypercalcemia; Hyperparathyroidism; Parathyroid

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCITONIN; CINACALCET; CLODRONIC ACID; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETIDRONIC ACID; FLUOROURACIL; GENE PRODUCT; GLUCOCORTICOID; HYDROCORTISONE; MITHRAMYCIN; PAMIDRONIC ACID; RISEDRONIC ACID; VINCRISTINE; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; AVASCULAR NECROSIS; CANCER ADJUVANT THERAPY; CARCINOGENESIS; CHROMOSOME; CUSHINGOID SYNDROME; EXTERNAL BEAM RADIOTHERAPY; GENE; GENE EXPRESSION; GENE MUTATION; HETEROZYGOSITY LOSS; HRPT2 GENE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; NEPHROTOXICITY; PARATHYROID CARCINOMA; PARATHYROID DISEASE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

CHEMOTHERAPY, ADJUVANT; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, PRIMARY; PARATHYROID NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 33646713394     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000198019.53606.2b     Document Type: Review

References (48)

1. Cohn K, Silverman M, Corrado J, Sedgewick C. Parathyroid carcinoma: the Lahey Clinic experience. Surgery 1985; 98:1095-1100.
2. Hakaim AG, Esselstyn CB Jr. Parathyroid carcinoma: 50-year experience at the Cleveland Clinic Foundation. Cleve Clin J Med 1993; 60:331-335.
3. Wang CA, Gaz RD. Natural history of parathyroid carcinoma: diagnosis, treatment, and results. Am J Surg 1985; 149:522-527.
4. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the US between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1999; 86:538-544.
5. Koea JB, Shaw JH. Parathyroid cancer: biology and management. Surg Oncol 1999; 8:155-165.
6. Iacobone M, Ruffolo C, Lumachi F, Favia G. Results of iterative surgery for persistent and recurrent parathyroid carcinoma. Langenbecks Arch Surg 2005; 390:385-390. This retrospective review reveals the difficulty of curing recurrent parathyroid carcinoma through repeated attempts at surgical resection. The authors underscore the importance of en bloc resection at the time of initial surgical therapy.
7. Holmes EC, Morton DL, Ketcham AS. Parathyroid carcinoma: a collective review. Ann Surg 1969; 169:631-640.
8. Kleinpeter KP, Lovato JF, Clark PB, et al. Is parathyroid carcinoma indeed a lethal disease? Ann Surg Oncol 2005; 12:260-266. A retrospective review of 23 patients with parathyroid carcinoma. The authors emphasize the indolent course of this disease in the majority of patients and the potential for long-term survival despite recurrent and metastatic disease.
9. Busaidy NL, Jimenez C, Habra MA, et al. Parathyroid carcinoma: a 22-year experience. Head Neck 2004; 26:716-726. A summary of the M.D. Anderson experience with parathyroid carcinoma over the last 22 years. Their data suggest that adjuvant radiotherapy improves survival. They stress the importance of a multidisciplinary approach to this disease.
10. Ireland JP, Fleming SJ, Levison DA, et al. Parathyroid carcinoma associated with chronic renal failure and previous radiotherapy to the neck. J Clin Pathol 1985; 38:1114-1118.
11. Shaha AR, Shah JP. Parathyroid carcinoma: a diagnostic and therapeutic challenge. Cancer 1999; 86:378-380.
12. Arslan N, Rydzewski B. Detection of a recurrent parathyroid carcinoma with FDG positron emission tomography. Clin Nucl Med 2002; 27:221-222.
13. Daly BD, Coffey SL, Behan M. Ultrasonographic appearances of parathyroid carcinoma. Br J Radiol 1989; 62:1017-1019.
14. Al-Sobhi S, Ashari LH, Ingemansson S. Detection of metastatic parathyroid carcinoma with Tc-99m sestamibi imaging. Clin Nucl Med 1999; 24:21-23.
15. Harach HR. The parathyroid. In: Lloyd RV, editor. Endocrine pathology: differential diagnosis and molecular advances. Totowa, NJ: Humana Press; 2004. pp. 109-122. This chapter provides a thorough description of the histopathologic hallmarks of parathyroid carcinoma in comparison with other parathyroid disorders.
16. Schantz A, Castleman B. Parathyroid carcinoma: a study of 70 cases. Cancer 1973; 31:600-605.
17. Bondeson L, Sandelin K, Grimelius L. Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Path 1993; 17:820-829.
18. Clayman GL, Gonzalez HE, El-Naggar A, Vassilopoulou-Sellin R. Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer 2004; 100:900-905.
19. Kennett S, Pollick H. Jaw lesions in familial hyperparathyroidism. Oral Surg Oral Med Oral Pathol 1971; 31:502-510.
20. Jackson CE, Norum RA, Boyd SB, et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery 1990; 108:1006-1012; discussion 1012-1013.
21. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 2002; 32:676-680.
22. Shattuck TM, Kim TS, Costa J, et al. Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin Endocrinol (Oxf) 2003; 59:180-189.
23. Howell VM, Haven CJ, Kahnoski K, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 2003; 40:657-663.
24. Tan MH, Morrison C, Wang P, et al. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 2004; 10:6629-6637.
25. Haven CJ, Howell VM, Eilers PH, et al. Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res 2004; 64:7405-7411.
26. Cryns VL, Thor A, Xu HJ, et al. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 1994; 330:757-761.
27. Dotzenrath C, Teh BT, Farnebo F, et al. Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors? J Clin Endocrinol Metab 1996; 81:3194-3196.
28. Pearce SH, Trump D, Wooding C, et al. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol (Oxf) 1996; 45:195-200.
29. Hunt JL, Carty SE, Yim JH, et al. Allelic loss in parathyroid neoplasia can help characterize malignancy. Am J Surg Pathol 2005; 29:1049-1055. This study revealed an increased level of allelic loss at chromosomal segments known to contain tumor suppressor genes in tissue from parathyroid carcinomas. The data support previous genetic studies and suggest involvement of specific areas of the genome in the pathogenesis of this disease.
30. Trigonis C, Cedermark B, Willems J, et al. Parathyroid carcinoma: problems in diagnosis and treatment. Clin Oncol 1984; 10:11-19.
31. Ellis JT, Barr DP. Metastasizing carcinoma of the parathyroid gland with osteitis fibrosa cystica and extensive calcinosis. Am J Pathol 1951; 27:383-397.
32. Wiseman SM, Rigual NR, Hicks WL Jr, et al. Parathyroid carcinoma: a multicenter review of clinicopathologic features and treatment outcomes. Ear Nose Throat J 2004; 83:491-494.
33. Calandra DB, Chejfec G, Foy BK, et al. Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery 1984; 96:1132-1137.
34. Bukowski RM, Sheeler L, Cunningham J, Esselstyn C. Successful combination chemotherapy for metastatic parathyroid carcinoma. Arch Intern Med 1984; 144:399-400.
35. Wynne AG, van Heerden J, Carney JA, Fitzpatrick LA. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore) 1992; 71:197-205.
36. Chow E, Tsang RW, Brierley JD, Filice S. Parathyroid carcinoma: the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 1998; 41:569-572.
37. Munson ND, Foote RL, Northcutt RC, et al. Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer 2003; 98:2378-2384.
38. Newrick PG, Braatvedt GD, Webb AJ, et al. Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate. Postgrad Med J 1994; 70:231-232.
39. Mann K. Oral biphosphonate therapy in metastatic parathyroid carcinoma. Lancet 1985; 1:101-102.
40. Jungst D. Disodium clodronate effective in management of severe hypercalcaemia caused by parathyroid carcinoma. Lancet 1984; 2:1043.
41. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19:558-567.
42. Bounameaux HM, Schifferli J, Montani JP, et al. Renal failure associated with intravenous diphosphonates. Lancet 1983; 1:471.
43. Lugassy G. 'Safety and convenience of a 15-minute infusion of zoledronic acid': not so safe. Oncologist 2005; 10:309-310; author reply 311-312.
44. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61:1115-1117.
45. Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998; 95:4040-4045.
46. Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:135-141. A randomized controlled trial demonstrating the efficacy of cinacalcet for normalizing calcium and decreasing PTH levels in patients with primary hyperparathyroidism.
47. Collins MT, Skarulis MC, Bilezikian JP, et al. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998; 83:1083-1088.
48. Pecherstorfer M, Brenner K, Zojer N. Current management strategies for hypercalcemia. Treat Endocrinol 2003; 2:273-292.